Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements.
Alzheimer’s disease
Biomarkers
Cerebrospinal fluid
Plaque, Amyloid
Positron emission tomography
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
21
06
2021
accepted:
26
10
2021
pubmed:
6
11
2021
medline:
16
3
2022
entrez:
5
11
2021
Statut:
ppublish
Résumé
Alzheimer's disease (AD) diagnosis can be hindered by amyloid biomarkers discordances. We aim to interpret discordances between amyloid positron emission tomography (Amy-PET) and cerebrospinal fluid (CSF) (Aβ Thirty-six subjects with dementia or mild cognitive impairment, assessed by neuropsychological tests, structural and functional imaging, and CSF assays (Aβ Groups were defined basing on the agreement among CSF Aβ The amyloid discordant cases could be overcome by combining CSF Aβ
Sections du résumé
BACKGROUND
BACKGROUND
Alzheimer's disease (AD) diagnosis can be hindered by amyloid biomarkers discordances.
OBJECTIVE
OBJECTIVE
We aim to interpret discordances between amyloid positron emission tomography (Amy-PET) and cerebrospinal fluid (CSF) (Aβ
METHOD
METHODS
Thirty-six subjects with dementia or mild cognitive impairment, assessed by neuropsychological tests, structural and functional imaging, and CSF assays (Aβ
RESULTS
RESULTS
Groups were defined basing on the agreement among CSF Aβ
CONCLUSION
CONCLUSIONS
The amyloid discordant cases could be overcome by combining CSF Aβ
Identifiants
pubmed: 34739618
doi: 10.1007/s10072-021-05704-2
pii: 10.1007/s10072-021-05704-2
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Peptide Fragments
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2469-2480Informations de copyright
© 2021. Fondazione Società Italiana di Neurologia.
Références
Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562
pubmed: 29653606
pmcid: 5958625
De Wilde A, Reimand J, Teunissen CE et al (2019) Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther 11(1):78 (Published 2019 Sep 12)
pubmed: 31511058
pmcid: 6739952
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368(9533):387–403
pubmed: 16876668
Palmqvist S, Mattsson N, Hansson O (2016) Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain 139(Pt 4):1226–1236
pubmed: 26936941
pmcid: 4806222
Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012 Aug;11(8):658]. Lancet Neurol 11(8):669–678
pubmed: 22749065
Sperling RA, Aisen PS, Beckett LA et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292
pubmed: 21514248
pmcid: 3220946
Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 13(6):614–629 [published correction appears in Lancet Neurol. 2014 Aug;13(8):757]
pubmed: 24849862
Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279
pubmed: 21514249
pmcid: 3312027
McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269
pubmed: 21514250
pmcid: 3312024
Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36(5):297–309
pubmed: 25840462
Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P (2019) Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease. Alzheimers Res Ther 11(1):34 (Published 2019 Apr 22)
pubmed: 31010420
pmcid: 6477717
Mattsson N, Insel PS, Landau S et al (2014) Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer’s disease. Ann Clin Transl Neurol 1(8):534–543
pubmed: 25356425
pmcid: 4184556
Landau SM, Lu M, Joshi AD et al (2013) Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. AnnNeurol 74(6):826–836
Mattsson N, Insel PS, Donohue M et al (2015) Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer’s disease. Brain 138(Pt 3):772–783
pubmed: 25541191
Wiltfang J, Esselmann H, Bibl M et al (2007) Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load. J Neurochem 101(4):1053–1059
pubmed: 17254013
Janelidze S, Zetterberg H, Mattsson N et al (2016) J CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol 3(3):154–165
pubmed: 27042676
pmcid: 4774260
Lewczuk P, Lelental N, Spitzer P, Maler JM, Kornhuber J (2015) Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer’s disease: validation of two novel assays. J Alzheimers Dis 43(1):183–191
pubmed: 25079805
Giacomucci G, Mazzeo S, Bagnoli S et al (2021) Matching clinical diagnosis and amyloid biomarkers in alzheimer’s disease and frontotemporal dementia. J Pers Med 11(1):47
pubmed: 33466854
pmcid: 7830228
Augutis K, Axelsson M, Portelius E et al (2013) Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis. Mult Scler 19(5):543–552
pubmed: 23069872
Zwan M, van Harten A, Ossenkoppele R et al (2014) Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. J Alzheimers Dis 41(3):801–807
pubmed: 24705549
Alongi P, Sardina DS, Coppola R et al (2019) 18F-Florbetaben PET/CT to Assess Alzheimer’s Disease: a new analysis method for regional amyloid quantification. J Neuroimaging 29(3):383–393
pubmed: 30714241
Meyer PF, McSweeney M, Gonneaud J, Villeneuve S (2019) AD molecular: PET amyloid imaging across the Alzheimer’s disease spectrum: from disease mechanisms to prevention. Prog Mol Biol Transl Sci 165:63–106
pubmed: 31481172
Lombardi G, Pupi A, Bessi V et al (2020) Challenges in Alzheimer’s disease diagnostic work-up: amyloid biomarker incongruences. J Alzheimers Dis 77(1):203–217
pubmed: 32716357
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol 149(2):351–356
pubmed: 3496763
Rudilosso S, San Román L, Blasco J, Hernández-Pérez M, Urra X, Chamorro Á (2017) Evaluation of white matter hypodensities on computed tomography in stroke patients using the Fazekas score. Clin Imaging 46:24–27
pubmed: 28688243
Kollhoff AL, Howell JC, Hu WT (2018) Automation vs experience: measuring Alzheimer’s beta-amyloid 1–42 peptide in the CSF. Front Aging Neurosci 10:253 (Published 2018 Aug 22)
pubmed: 30186152
pmcid: 6113375
Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ (1994) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2(4):189–210
Della Rosa PA, Cerami C, Gallivanone F et al (2014) A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 12(4):575–593
pubmed: 24952892
Perani D, Della Rosa PA, Cerami C et al (2014) Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage Clin 2014(6):445–454
Rolls ET, Huang CC, Lin CP, Feng J, Joliot M (2020) Automated anatomical labelling atlas 3. Neuroimage. 206:116189
pubmed: 31521825
Palmqvist S, Zetterberg H, Mattsson N et al (2015) Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology 85(14):1240–1249
pubmed: 26354982
pmcid: 4607601
Nobili F, Arbizu J, Bouwman F et al (2018) European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
pubmed: 29932266
Fodero-Tavoletti MT, Cappai R, McLean CA et al (2009) Amyloid imaging in Alzheimer’s disease and other dementias. Brain Imaging Behav 3(3):246–261
pubmed: 22005989
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259
pubmed: 1759558
Palmqvist S, Schöll M, Strandberg O et al (2017) Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun 8(1):1214
pubmed: 29089479
pmcid: 5663717
Berti V, Pupi A, Mosconi L (2011) PET/CT in diagnosis of dementia. Ann N Y Acad Sci 1228:81–92
pubmed: 21718326
pmcid: 3692287
Nelson PT, Abner EL, Schmitt FA et al (2009) Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from alzheimer disease. J Neuropathol Exp Neurol 68(7):774–784
pubmed: 19535994
Weigand AJ, Bangen KJ, Thomas KR et al (2020) Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity. Brain Commun 2(1):fcz046
pubmed: 32051933
Weise D, Tiepolt S, Awissus C et al (2015) Critical Comparison of Different Biomarkers for Alzheimer’s Disease in a Clinical Setting. J Alzheimers Dis 48(2):425–432
pubmed: 26402006
Herholz K, Salmon E, Perani D et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17(1):302–316
pubmed: 12482085
Karas G, Scheltens P, Rombouts S et al (2007) Precuneus atrophy in early-onset Alzheimer’s disease: A morphometric structural MRI study. Neuroradiology 49(12):967–976
pubmed: 17955233